LLG783

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LLG783, covering 2020-01-31 to 2020-01-31. Get the full timeline:

Most recent: Clinical Trial Update: Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication [Phase 2]